IPO registrations (S-1, F-1) · Registrants
Merus N.V.
- SEC CIK
- 1651311 · filings on EDGAR ↗
- Former names
- Merus B.V. (2015–2016)
- Registration
- Form F-1, first filed 2015-10-19, last 2019-04-03; 2 initial registrations, 4 amendments
- Outcome
- Final prospectus filed 2016-05-20; declared effective 2016-05-18
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- P7
- Business address
- YALELAAN 62, 3584 Cm Utrecht, DE
- EDGAR entity type
- operating
- Insiders and CEO pay
- Merus N.V. on the corporate pages
Offering terms
- Proposed price range
- $14.00–$16.00 per share (F-1/A filed 2016-05-09)
- Final price
- $10.00 per share, below the range (424B4 filed 2016-05-20, an initial public offering)
- Shares sold
- 5,500,000
- Gross proceeds
- $55,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol MRUS
- Lead underwriters
- Citigroup
- Syndicate
- Jefferies; Guggenheim Securities; Wedbush Securities
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: Merus N.V. EXACT (CIK (EXACT))
- SEC filer: Merus N.V. EXACT (CIK (EXACT))
Filings 14
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2015-10-19 | F-1 | F-1 (foreign registration) | Merus B.V. | 0001193125-15-346981 ↗ |
| 2016-01-21 | F-1/A | F-1/A (amendment) | Merus B.V. | 0001193125-16-434605 ↗ |
| 2016-04-08 | F-1/A | F-1/A (amendment) | Merus B.V. | 0001193125-16-535709 ↗ |
| 2016-05-09 | F-1/A | F-1/A (amendment) | Merus B.V. | 0001193125-16-582683 ↗ |
| 2016-05-18 | EFFECT | EFFECT (declared effective) | Merus B.V. | 9999999995-16-004704 ↗ |
| 2016-05-20 | 424B4 | 424B4 (final prospectus) | Merus N.V. | 0001193125-16-597603 ↗ |
| 2017-06-16 | EFFECT | EFFECT (declared effective) | Merus N.V. | 9999999995-17-001570 ↗ |
| 2018-12-27 | F-1 | F-1 (foreign registration) | Merus N.V. | 0001193125-18-359219 ↗ |
| 2019-04-03 | F-1/A | F-1/A (amendment) | Merus N.V. | 0001193125-19-096714 ↗ |
| 2019-04-05 | EFFECT | EFFECT (declared effective) | Merus N.V. | 9999999995-19-000618 ↗ |
| 2019-08-27 | EFFECT | EFFECT (declared effective) | Merus N.V. | 9999999995-19-001976 ↗ |
| 2019-08-29 | EFFECT | EFFECT (declared effective) | Merus N.V. | 9999999995-19-002012 ↗ |
| 2020-05-05 | EFFECT | EFFECT (declared effective) | Merus N.V. | 9999999995-20-001033 ↗ |
| 2020-05-05 | EFFECT | EFFECT (declared effective) | Merus N.V. | 9999999995-20-001034 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2016-05-09 | F-1/A | registration statement | $14.00–$16.00 | $15.00 | 4,333,333 | $64,999,995 | Nasdaq MRUS | 4 | primary document; range, price sentence, shares headline, proceeds computed, cover names 4 | document ↗ |
| 2016-05-20 | 424B4 | final prospectus | $10.00 | 5,500,000 | $55,000,000 | Nasdaq MRUS | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| INCYTE CORP | TenPercentOwner | 3 | 2017–2021 | ||
| Bakker Lex | Officer | SVP, Chief Development Officer | 20 | 2020–2022 | |
| de Koning John | Director | 1 | 2020 | ||
| de Kruif John | Officer | Chief Technology Officer; SVP & Chief Technology Officer | 20 | 2020–2022 | |
| Greig Russell | Director | 1 | 2020 | ||
| Iwicki Mark T | Director | 9 | 2020–2025 | ||
| Kanavy Len | Director | 8 | 2020–2025 | ||
| Liu Hui | Officer | EVP, CBO & Head of Merus US | 21 | 2020–2024 | |
| Lundberg Sven Ante | Director,Officer | President, CEO & PEO; President, CEO & PFO | 21 | 2020–2025 | |
| Mehra Anand | Director | 8 | 2020–2025 | ||
| PERRY GREGORY D | Director; Officer | Chief Financial Officer; Chief Financial Officer & PFO | 9 | 2020–2025 | |
| Sandor Victor | Director | 8 | 2020–2025 | ||
| Shuman Harry | Officer | Chief Accounting Officer; VP Controller, PAO | 26 | 2020–2025 | |
| Silverman Peter B. | Officer | COO & GC; EVP, GC and Head of Utrecht; EVP & General Counsel | 17 | 2020–2025 | |
| Sirulnik Andres | Officer | EVP & Chief Medical Officer | 2 | 2020 | |
| Throsby Mark | Officer | EVP & Chief Scientific Officer | 15 | 2020 | |
| BIOTECHNOLOGY VALUE FUND II LP | Other | 15 | 2020–2021 | ||
| BIOTECHNOLOGY VALUE FUND L P | Other; TenPercentOwner | 15 | 2020–2021 | ||
| Biotechnology Value Trading Fund OS LP | Other | 15 | 2020–2021 | ||
| BVF INC/IL | TenPercentOwner | 15 | 2020–2021 | ||
| BVF PARTNERS L P/IL | TenPercentOwner | 15 | 2020–2021 | ||
| BVF Partners OS Ltd. | Other | 15 | 2020–2021 | ||
| LAMPERT MARK N | TenPercentOwner | 15 | 2020–2021 | ||
| BVF GP HOLDINGS LLC | Other; TenPercentOwner | 13 | 2020–2021 | ||
| BVF I GP LLC | Other; TenPercentOwner | 13 | 2020–2021 | ||
| BVF II GP LLC | Other | 13 | 2020–2021 | ||
| Pucci Paolo | Director | 8 | 2020–2025 | ||
| Joe Andrew | Officer | SVP, CMO | 6 | 2020–2024 | |
| Geuijen Cecile A W | Officer | SVP & Chief Scientific Officer | 3 | 2021–2022 | |
| GOWEN MAXINE | Director | 8 | 2021–2025 | ||
| Haddock Jason | Director | 4 | 2024–2025 | ||
| Zohren Fabian | Officer | Chief Medical Officer | 4 | 2024–2025 | |
| GENMAB A/S | TenPercentOwner | 5 | 2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2019-01-02 | Merus N.V. | Biotechnology | $15,000,000 | $15,000,000 | 1 | 1 |
| 2018-02-28 | Merus N.V. | Biotechnology | $55,799,946 | $55,799,946 | 9 | 1 |
| 2017-01-24 | Merus N.V. | Biotechnology | $80,000,000 | $80,000,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Merus N.V. | Form D private offerings | CIK (EXACT) | |
| SEC filer | Merus N.V. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, DE first:
- Prelude Therapeutics Inc DE
- NRX Pharmaceuticals, Inc. DE
- Applied Molecular Transport Inc. DE
- Lomond Therapeutics Holdings, Inc. DE
- NovaCardia Inc CA
- MyoKardia, Inc. CA
- Bioquest Corp CA
- Regen BioPharma Inc CA
- Catalent, Inc. NJ
- Korro Bio, Inc. MA
In other datasets, the same topic (Health) in DE:
- Nonprofit: 1212 CORPORATION (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health